Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7306066 | 0.80 | KDM4E (0.45) | KDM4EHSD17B10CYP1A2ALDH1A1LMNA | |
| SCHEMBL7299383 | 0.80 | ALDH1A1 (0.43) | APOBEC3GKDM4EHSD17B10ALDH1A1LMNA | |
| SCHEMBL7435538 | 0.79 | GRM5 (0.38) | APOBEC3GHSD17B10CYP1A2ALDH1A1MAPT | |
| SCHEMBL7304540 | 0.75 | KDM4E (0.40) | KDM4EHSD11B1 | |
| SCHEMBL10669541 | 0.74 | TDP2 (0.46) | KDM4EHSD17B10CYP1A2CYP2C9ACHE | |
| SCHEMBL8762409 | 0.73 | APOBEC3G (0.63) | RXFP1APOBEC3GKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL10469336 | 0.72 | HSD11B1 (0.48) | APOBEC3GALDH1A1LMNAMAPTHPGD | |
| SCHEMBL7485829 | 0.72 | LMNA (0.50) | APOBEC3GKDM4EHSD17B10CYP1A2CYP2C9 | |
| SCHEMBL8763630 | 0.71 | HSD11B1 (0.50) | RXFP1APOBEC3GKDM4EHSD17B10CYP1A2 | |
| SCHEMBL7297002 | 0.71 | TDP1 (0.45) | RXFP1APOBEC3GKDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. | 2023-12-21 | — | — | US | claimed |
| EP-4247386-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | Bexson Biomedical, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| WO-2022109052-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-10716779-B2 | Methods and compositions for treating foot or hand pain | SANDERS JENNIFER L (US) | 2020-07-21 | — | — | US | claimed |
| US-20190083465-A1 | Methods And Compositions For Treating Foot Or Hand Pain | SANDERS JENNIFER L (US) | 2019-03-21 | — | — | US | claimed |
| US-10195180-B2 | Methods and compositions for treating foot or hand pain | SANDERS JENNIFER L (US) | 2019-02-05 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0769009-A1 | PROCESS FOR THE PREPARATION OF 5-ARYL-2,4-DIALKYL-3H-1,2,4-TRIAZOLE-3-THIONES | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-23 | — | — | EP | claimed |
| EP-0452926-B1 | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers | MERRELL DOW PHARMA (US) | 1996-03-13 | — | — | EP | claimed |
| WO-1996001812-A1 | PROCESS FOR THE PREPARATION OF 5-ARYL-2,4-DIALKYL-3H-1,2,4-TRIAZOLE-3-THIONES | MERRELL PHARMACEUTICALS INC. (US) | 1996-01-25 | — | — | WO | claimed |
| US-5331002-A | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-07-19 | — | — | US | claimed |
| US-5236942-A | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful in the treatment of Altzheimer's dementia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-17 | — | — | US | claimed |
| US-5100906-A | 5-ARYL-4-ALKYL-3H-1,2,4-TRIAZOLE-3-THIONES USEFUL AS MEMORY ENHANCERS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-31 | — | — | US | claimed |
| EP-0452926-A2 | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-23 | — | — | EP | claimed |
| US-4912095-A | 5-aryl-2,4-dialkyl-3H-1,2,4-triazole-3-thiones useful as antidepressants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-27 | — | — | US | claimed |
| US-4775688-A | 5-aryl-2,4-dialkyl-3H-1,2,4-triazole-3-thiones and their use as antidepressants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | GABBR1, GABBR2, GABRB2 | RXFP1 288/4885APOBEC3G 3523/4885KDM4E 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.